Clinical Trial Update: Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating efficacy and safety of lanadelumab (SHP643) in Japanese participants with hereditary angioedema has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Lanadelumab (lanadelumab)

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: COMPLETED | Results posted: 2022-09-19